HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform

• Hims & Hers added eight new partners, expanding its Benefits program across fitness, nutrition, glucose monitoring, women's health and sleep.
• The company recently launched generic Semaglutide in Canada, marking its first international rollout of a generic GLP-1 product.
• Hims is also expanding into AI healthcare through Labs AI, while investors are closely watching peptides as a potential future growth driver.

Shares of Hims & Hers Health, Inc. (HIMS) are headed for their best week in over a month as the company unveiled eight new partnerships spanning fitness, nutrition and preventive health, underscoring its push to become a full-stack healthcare platform rather than a provider of individual treatments.

HIMS Stock jumped nearly 1% on Thursday, with shares on track to snap a two-week losing streak and recover from a slump that put the stock on pace for its worst month since February. 

Hims’ All-In-One Health Platform 

The company expanded its Hims & Hers Benefits program with new partners, including iFIT, Ladder, Pvolve, HelloFresh, Factor, MyFitnessPal, Stelo by Dexcom, Flo Health and Natural Cycles. The additions bring the total number of participating brands to 10 and broaden the platform's services across exercise, nutrition, glucose monitoring, women's health and sleep-related services.

The telehealth firm has also integrated Dexcom’s Stelo continuous glucose monitor, joining founding partners Prenuvo and Eight Sleep. Hims & Hers said that it is passing the negotiated discounts and trials directly to active subscribers without taking a profit cut. 

CEO Andrew Dudum said on X that the company's vision is "not just a solution for a single condition, but an entire health ecosystem that gets you healthy, keeps you healthy, and adapts to the way your health evolves over time, both on and off the platform."

"We're making it easier and more affordable to sleep better, eat better, move better, and recover better," Dudum said. The expansion comes amid Hims' efforts to grow beyond its core prescription business. Over the past year, the company has pushed into diagnostics, hormone health, preventive care and AI-based healthcare tools.

Hims’ New Growth Drivers

Last week, the company launched generic Semaglutide in Canada through a partnership with Apotex after the early expiration of Novo Nordisk's Canadian Semaglutide patent. The launch marked Hims' first international rollout of a generic GLP-1 product and expanded its weight-loss business beyond the U.S.

The company previously benefited from strong demand for compounded GLP-1 treatments during shortages of Wegovy and Zepbound before expanding its platform to include branded therapies such as Wegovy, Ozempic, Zepbound and Mounjaro.

Additionally, Hims launched Labs AI earlier this month, introducing a healthcare assistant that helps users interpret lab results, biomarker trends, and long-term health risks through personalized analysis. Investors are also focusing on peptides as a key growth catalyst for Hims, ahead of upcoming FDA regulatory discussions regarding which peptide compounds will remain eligible for pharmacy compounding. 

Wall Street Remains Divided On HIMS

The expansion comes just days after David Wells, the former CFO of Netflix, signaled confidence in the telehealth firm by buying new shares. According to a recent filing, Wells acquired 48,400 shares of Hims at $24.24 per share, increasing his holdings to 224,417 shares. The purchase was valued at $1.17 million.

However, Bank of America Securities (BofA) recently lowered its price target on Hims to $25 from $28, while maintaining a ‘Neutral’ rating. The firm said that the company's 2026 outlook depends on a “significant acceleration” in GLP-1 growth and may not fully account for pricing pressure and increasing competition in the weight-loss market.

The downgrade came after Hims' first-quarter results, which fell short of analyst expectations on both revenue and earnings. Hims raised its 2026 outlook and now expects revenue of $2.8 billion to $3 billion and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $275 million to $350 million.

How Do Retail Traders Feel About HIMS?

On Stocktwits, retail sentiment for HIMS was ‘bearish’ amid ‘extremely low’ message volume.

One user said, “No one’s talking about how these peptides could have cancer-stalling properties. If that’s proven and they start utilizing the peptides for that…this hits 70.”

Another user said, “$HIMS This is going to run to $40 soon. I think it could happen in June.”

HIMS stock has declined 52% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: ASTS Stock Slides Overnight: Blue Origin Explosion Raises Fresh Fears For 45-Satellite Rollout